Lupin Launches Liraglutide Injection in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States.

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza® Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus.

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen (RLD Victoza®) had an estimated annual sale of USD 350 million in the U.S. (IQVIA MAT Aug 2025).

Spiro Gavaris, President - U.S. Generics, Lupin, said, "We are pleased to launch Liraglutide Injection in the U.S. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients."

Shares of Lupin Limited was last trading in BSE at Rs. 1972.00 as compared to the previous close of Rs. 1981.70. The total number of shares traded during the day was 15266 in over 1659 trades.

The stock hit an intraday high of Rs. 2005.75 and intraday low of 1969.80. The net turnover during the day was Rs. 30366388.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Liraglutide Injection USLaunch